Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panzyga in pediatric chronic ITP
NCT03866798Phase 4Terminated
- Sponsor
- Octapharma
- Start
- Jan 2020
- Primary completion
- Sep 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of intravenous immunoglobulin G in immune thrombocytopenia (ITP), sponsored by Octapharma. Primary endpoint: Platelet Count Increase at 8 days. Started Jan 2020; status: terminated.
02
Drugs
intravenous immunoglobulin G
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT03866798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03866798.